Abstract
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Current Cancer Drug Targets
Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Volume: 16 Issue: 5
Author(s): José Ángel García-Sáenz, Miguel Martín, Pilar Zamora, Ignasi Tusquets, Miguel Ángel Seguí, Ana Santaballa, Pedro Sánchez-Rovira, Manuel Ruiz, Álvaro Rodríguez-Lescure, Arrate Plazaola, Eduardo Martínez de Dueñas, Noelia Martínez-Jáñez, Guillermo López-Vivanco, Rafael López, Juan de la Haba, Antonio González-Martín, Andrés García-Palomo, Elena Galve, Lourdes Calvo, Norberto Batista, Agustí Barnadas, Francisco Ayala de la Peña, José Manuel Aramendía, Isabel Álvarez, Raquel Andrés, Ana Lluch, Antonio Llombart, Javier Cortés, Eva Ciruelos and Emilio Alba
Affiliation:
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Abstract: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Export Options
About this article
Cite this article as:
Ángel García-Sáenz José, Martín Miguel, Zamora Pilar, Tusquets Ignasi, Ángel Seguí Miguel, Santaballa Ana, Sánchez-Rovira Pedro, Ruiz Manuel, Rodríguez-Lescure Álvaro, Plazaola Arrate, Martínez de Dueñas Eduardo, Martínez-Jáñez Noelia, López-Vivanco Guillermo, López Rafael, de la Haba Juan, González-Martín Antonio, García-Palomo Andrés, Galve Elena, Calvo Lourdes, Batista Norberto, Barnadas Agustí, Ayala de la Peña Francisco, Manuel Aramendía José, Álvarez Isabel, Andrés Raquel, Lluch Ana, Llombart Antonio, Cortés Javier, Ciruelos Eva and Alba Emilio, Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009615666150817121731
DOI https://dx.doi.org/10.2174/1568009615666150817121731 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Cytogenetics of Autism
Current Genomics Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety History of Autoimmune Pancreatitis and Mikuliczs Disease
Current Immunology Reviews (Discontinued) Role of Metallothionein in Inflammatory Lung Diseases
Current Respiratory Medicine Reviews In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples
Current Pharmaceutical Analysis Metabolic Remodeling Induced by Adipocytes: A New Achilles' Heel in Invasive Breast Cancer?
Current Medicinal Chemistry Xenobiotic Nuclear Receptor-Mediated Regulation of UDP-Glucuronosyltransferases
Current Drug Metabolism P-Selectin Antagonism in Inflammatory Disease
Current Pharmaceutical Design False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Preparation and Characterization of the Nutritive Value of Flour Made from Acai (Euterpe oleracea, Mart.) Seeds
The Natural Products Journal Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry CD4+CD25+ T Regulatory Cells and TGF-β in Mucosal Immune System: The Good and the Bad
Current Medicinal Chemistry Metallothioneins and Cancer
Current Protein & Peptide Science Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design